Universities in Germany and Sweden Lose Access to Elsevier Journals

Consortia in both countries are pushing for open-access subscriptions with the publisher.

Written byDiana Kwon
| 3 min read
Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

This month, approximately 300 academic institutions in Germany and Sweden lost access to new papers published in Elsevier’s journals due to a standstill in negotiations for nationwide subscription contracts. While Elsevier’s papers remain inaccessible, academics are turning to alternative means of obtaining them, such as using inter-library loan services, emailing authors, finding earlier versions on preprint servers, or buying individual papers.

“Of course, we can’t deny that it’s a loss not being able to have a complete [collection] of scientific papers in front of you and just screen through them,” says Anders Götherström, an archeologist at Stockholm University. “But I imagine eventually, we will still find a way to get the papers that we want to get.”

Josef Pfeilschifter, a pharmacologist and toxicologist at Goethe University Frankfurt, is very concerned about the loss of access to Elsevier’s journals at his institution. “For life scientists and medical scientists, [Elsevier’s titles include] ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Diana is a freelance science journalist who covers the life sciences, health, and academic life. She’s a regular contributor to The Scientist and her work has appeared in several other publications, including Scientific American, Knowable, and Quanta. Diana was a former intern at The Scientist and she holds a master’s degree in neuroscience from McGill University. She’s currently based in Berlin, Germany.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies